A recent letter published in the Journal of the American College of Cardiology calls for greater recognition of the Coronary Sinus Reducer as an innovative therapy for patients with refractory angina.

Left main coronary artery disease patients undergoing CABG in the EXCEL trial have higher 5-year major bleed rates than those on PCI, but PCI carries a greater risk of post-discharge bleeding.

Intravascular Lithotripsy has demonstrated “encouraging” outcomes in off-label use for the treatment of in-stent restenosis and warrants further studies to pin-down optimal use and long-term effects, according to a new research letter analyzing NCDR data.

Research published in JACC: Cardiovascular Interventions identifies the significant differences between fibrotic and calcific forms of aortic stenosis (AS), as researchers reveal further insights into patient characteristics and outcomes post-transcatheter aortic valve replacement (TAVR). 

Dedicated transcatheter aortic valve replacement devices led to better outcomes in high-risk severe native aortic regurgitation patients than off-label alternatives, according to a new meta-analysis in more than 2,000 patients.

A retrospective analysis finds no significant difference in key long-term outcomes between two advanced transcatheter heart valves in findings that provide critical insights for optimizing valve selection in transcatheter aortic valve replacement (TAVR) procedures.

Both genetic and social factors should play a joint role in boosting the accuracy of risk modelling for coronary heart disease (CHD), said the authors of a new analysis of the ‘All of Us’ (AoU) program, stressing that racial identity is a crucial driver behind bigger social burden.

A recent review reveals the significant risks heart failure patients face if they discontinue long-term drug treatments, which can include a rapid return to baseline and worsening rebound.

The review focuses on patients with heart failure with reduced ejection fraction (HFrEF) and warns of persistent cardiovascular deterioration and a gradual decline from long-term benefits for those abruptly stopping foundational heart medications, even for short periods.

“The totality of available evidence points to a meaningful clinical deterioration within a few weeks following the withdrawal for most drugs that have been evaluated for the treatment of heart failure,” said the authors of the paper, which appears in the Journal of the American College of Cardiology.

“These findings suggest that that current emphasis on the implementation of foundational drugs needs to include an equally important emphasis to avoid even short-term gaps in treatment.”

A new article offers insight on the challenges of reducing mortality rates in patients with heart failure with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF).